Last updated: February 16, 2026
What Is the Current Market Status for NDC 66993-0142?
The drug identified by NDC 66993-0142 is Teprotumumab, marketed under the brand name Tepezza. Approved by the FDA in January 2020 for the treatment of thyroid eye disease (TED), it quickly gained market penetration due to its novel mechanism targeting insulin-like growth factor 1 (IGF-1) receptor pathways.
How Does Tepezza Fit Into the Market for Thyroid Eye Disease?
The global thyroid eye disease market is projected to grow from approximately $30 million in 2020 to $150 million by 2027. This growth stems from increased diagnosis rates, high unmet needs, and the adoption of Tepezza as the standard of care for TED.
Tepezza's market share remains strong, with the drug dominating the treatment landscape for active TED. It competes primarily against off-label therapies and corticosteroids, which have limited efficacy and safety concerns.
What Are the Pricing Trends for Tepezza?
Pricing models for Tepezza have remained relatively steady since its launch. The average wholesale price (AWP) is approximately $14,000 per infusion, with a typical treatment course involving 8 infusions over 4-6 months. This results in a total treatment cost of roughly $112,000 per patient.
In the United States, the net price after rebates and discounts averages between $10,000 and $12,000 per infusion, resulting in a total of $80,000 to $96,000 per course. The high cost presents both a barrier to access and a driver of revenue.
Global pricing varies significantly; in some European markets, Tepezza is priced approximately 25–30% lower due to pricing controls and reimbursement policies.
What Are the Revenue Projections for Tepezza?
Estimates forecast US sales to reach $1.5 billion annually by 2025, assuming continued growth in prescriptions and expanded indications. The market is expected to expand further through:
- Increased awareness and diagnosis of TED.
- Expanded indications such as chronic TED.
- Off-label use in other IGF-1 pathway-related disorders.
Sales growth relies heavily on the company's ability to maintain market exclusivity and navigate potential biosimilar competition.
How Might Biosimilar Competition Impact the Market and Pricing?
As of 2023, biosimilar development for Tepezza is in early stages, but FDA approval is anticipated within 3-5 years. The entry of biosimilars could result in a price reduction of 25–40%, significantly impacting revenue and market share.
The impact depends on regulatory pathways, patent litigation outcomes, and payer negotiations. Historically, biosimilar entry has shifted the market dynamics for biologics like adalimumab and infliximab, causing price declines and increased access.
What Are the Key Risks Influencing Market and Price Stability?
- Regulatory challenges or safety concerns could limit existing usage.
- Patent litigation could extend market exclusivity.
- Limited reimbursement or payer restrictions could reduce access.
- Off-label competition or new indications might alter demand.
Key Takeaways
- Tepezza (NDC 66993-0142) remains the dominant therapy for thyroid eye disease with stable pricing and robust revenue projections.
- US annual sales are expected to approach $1.5 billion by 2025.
- Market growth depends on increased diagnosis, indication expansion, and payer coverage.
- Biosimilar competition could lead to significant price reductions within 3-5 years.
- Market risks include regulatory hurdles, litigation, and payer restrictions.
FAQs
Q1: When was Tepezza approved by the FDA?
A1: January 2020.
Q2: What is the typical treatment cost for Tepezza in the US?
A2: Between $80,000 and $96,000 per patient per course.
Q3: How does biosimilar competition affect biologic drug markets?
A3: Biosimilars typically reduce prices by 25–40%, leading to increased market access and potential revenue declines for originators.
Q4: What other indications are under investigation for Tepezza?
A4: Expanded use in chronic TED and other IGF-1 related disorders.
Q5: What are the primary drivers of market growth for Tepezza?
A5: Increased diagnosis, recognition of its efficacy, and expanded payer coverage.
References
[1] FDA approval documentation for Tepezza (2020).
[2] Market research reports on thyroid eye disease.
[3] Industry analyses on biologic pricing trends and biosimilar impacts.
